Ticker
ADAP

Price
2.22
Stock movement up
+- (%)
Company name
Adaptimmune Therapeutics Plc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
359.68M
Ent value
526.80M
Price/Sales
38.72
Price/Book
2.20
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-55.15%
3 year return
15.79%
5 year return
-15.78%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ADAP does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF125.41
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales38.72
Price to Book2.20
EV to Sales56.71

FINANCIALS

Per share

Loading...
Per share data
Current share count162.02M
EPS (TTM)-1.09
FCF per share (TTM)-0.07

Income statement

Loading...
Income statement data
Revenue (TTM)9.29M
Gross profit (TTM)9.29M
Operating income (TTM)-124.36M
Net income (TTM)-170.17M
EPS (TTM)-1.09
EPS (1y forward)-0.83

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-1338.61%
Profit margin (TTM)-1831.79%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash89.54M
Net receivables42.89M
Total current assets359.46M
Goodwill0.00
Intangible assets788.00K
Property, plant and equipment0.00
Total assets419.80M
Accounts payable7.02M
Short/Current long term debt25.95M
Total current liabilities66.15M
Total liabilities256.65M
Shareholder's equity163.15M
Net tangible assets162.36M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)2.87M
Capital expenditures (TTM)14.58M
Free cash flow (TTM)-11.72M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-104.31%
Return on Assets-40.54%
Return on Invested Capital-102.59%
Cash Return on Invested Capital-7.06%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.27
Daily high2.33
Daily low2.17
Daily Volume154K
All-time high21.12
1y analyst estimate5.67
Beta1.84
EPS (TTM)-1.09
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ADAPS&P500
Current price drop from All-time high-89.49%-12.18%
Highest price drop-96.57%-56.47%
Date of highest drop15 Nov 20199 Mar 2009
Avg drop from high-69.23%-11.38%
Avg time to new high368 days12 days
Max time to new high1813 days1805 days
COMPANY DETAILS
ADAP (Adaptimmune Therapeutics Plc) company logo
Marketcap
359.68M
Marketcap category
Small-cap
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Employees
494
Investor relations
-
SEC filings
CEO
Adrian Rawcliffe
Country
USA
City
Abingdon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Adaptimmune Therapeutics plc (NASDAQ: ADAP) announces data from its signal-finding Phase 1 SURPASS trial of ADP-A2M4CD8 in solid tumor settings. The data will be presented at the European Society for ...
September 9, 2022
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development pl...
September 9, 2022
- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a l...
August 25, 2022
Today is shaping up negative for Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders, with the analysts...
August 10, 2022
- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phas...
August 4, 2022
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders should be happy to see the share price up 12% in the last...
August 1, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financ...
July 21, 2022
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
July 1, 2022
If you want to know who really controls Adaptimmune Therapeutics plc ( NASDAQ:ADAP ), then you'll have to look at the...
July 1, 2022
Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. To put this move into the proper context, the bellwether ...
June 27, 2022
Next page